Date: 05.06.2024
To,
The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001

SCRIP CODE: 541096

Sub: Acquisition of additional shares of Innoxel Lifesciences Pvt Ltd
Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulation"), we hereby inform you that Bharat Parenterals Ltd ("the Company") will acquire additional 99,85,477 equity shares having Face value Rs.10 per share with a premium of Rs. 54.90/- per share aggregating of Rs. 64.90/- per share of Innoxel Lifesciences Pvt Ltd, a Subsidiary company of the Company on a preferential basis. The details as required under Regulation 30 of the SEBI Listing Regulation and SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13,2023 are as under:

| a) Name of the target entity, details in brief such as size, turnover etc. | Innoxel Lifesciences Private Limited ("Innoxel")
Authorised capital: 10,00,00,000 equity shares of Rs.10 each aggregating to 1,00,00,00,000/-
Paid up capital: 9,00,14,523 equity shares of Rs.10 each aggregating to Rs. 90,01,45,230/-
Turnover for the year ended March 31, 2024: INR. 3,74,00,645/-
Net loss for the year ended March 31, 2024: Rs. (7,98,40,666/-). |

| b) whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; | The shares are allotted on a Preferential Basis to the existing shareholders. Share to be allotted on Preferential basis in favor of the Company. Innoxel Lifesciences Private Limited being a subsidiary of the Company covered under the definition of related party. However, issue of Equity shares on Preferential Basis does not considered as Related Party Transactions.
Mr. Bharat R. Desai Managing Director of the company is also Whole-time director in Innoxel Lifesciences Pvt Ltd. |

Mr. Bharat R. Desai Managing Director of the company is also Whole-time director in Innoxel Lifesciences Pvt Ltd.
<table>
<thead>
<tr>
<th><strong>c) Industry to which the entity being acquired belongs</strong></th>
<th>Manufacturing of Pharmaceuticals products</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>d) Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)</strong></td>
<td>Innoxel Lifesciences Private Limited is a subsidiary company of the Company. The investment is made for Expansion of Existing Plant and Working capital requirement of the Subsidiary Company.</td>
</tr>
<tr>
<td><strong>e) Brief details of any governmental or regulatory approvals required for the acquisition</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>f) Indicative time period for completion of the acquisition</strong></td>
<td>By June 30th, 2024 subject to approval of shareholders</td>
</tr>
<tr>
<td><strong>g) Nature of consideration - whether cash consideration or share swap and details of the same</strong></td>
<td>Cash consideration.</td>
</tr>
<tr>
<td><strong>h) Cost of acquisition or the price at which the shares are acquired</strong></td>
<td>Price at which the shares are acquired is Rs. 64.90/- per share including premium of Rs. 54.90/- per share as per Shareholding Agreement entered between the Company and other shareholders of Innoxel Lifesciences Pvt Ltd.</td>
</tr>
<tr>
<td><strong>i) Percentage of shareholding/control acquired and/or number of shares acquired</strong></td>
<td>Earlier the Company was holding 51.00% in Innoxel Lifesciences Pvt Ltd. After the proposed acquisition, the Company will hold 55.89% equity shares in Innoxel Lifesciences Pvt Ltd.</td>
</tr>
<tr>
<td><strong>j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</strong></td>
<td>Pharmaceuticals Manufacturing sector, the subsidiary formed to undertake manufacturing of pharmaceutical formulations. Date of incorporation: 16.10.2020 Last three years’ turnover: [below Fig. in Lakhs] 2021-22: 0.11 2022-23: 9.51 2023-24: 374.01 Country of presence: India</td>
</tr>
</tbody>
</table>

Kindly acknowledge the receipt and inform the members of the Exchanges.

Thank you,

FOR, BHARAT PARENTERALS LIMITED

Krutika Bhattbhatt
Company Secretary & Compliance Officer
M.No.- F11482